From 5AM's nest, neuroscience startup Nido Biosciences launches with $109M and PhI underway
After almost five years in stealth, precision neuroscience startup Nido Biosciences emerged Monday with $109 million and a Phase I study already in the works.
The biotech, led by former Syros Pharmaceuticals business chief and nearly three-decade Alexion veteran Jeremy Springhorn, is creating new small molecules for neurological diseases and aims to return cells to a healthy state.
The Watertown, MA-based biotech formed in 5AM Ventures’ so-called 4:59 Initiative, which has spawned gene therapy maker Homology Medicines, cell therapy biotech Ensoma and oncology-focused Ideaya Biosciences, among others.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.